Concord Biotech Ltd Share Price & Stock Analysis

Concord Biotech Ltd (NSE: CONCORDBIO, BSE: 543960) is an Ahmedabad, Gujarat-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹12,495 Cr, it ranks #528 by market cap among the 6,197 Indian listed companies on FinBizNet, and #8 of 11 in Pharmaceutical CDMO and CRO Services. At ₹595.00 (as of 16 Nov 2026), the share price is 26.3% below its 52-week high of ₹807.50 and 20.6% above its 52-week low of ₹493.50. The share price is down 14.8% over one year and down 18.3% over three months.

Key Metrics

Current Price₹595.00
Market Cap₹12,495 Cr
NSE SymbolCONCORDBIO
BSE Code543960
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services
Sub-IndustryLife Sciences Tools and Services > Pharmaceutical CDMO and CRO Services
P/E Ratio24.2
Return on Equity13.54%
Return on Assets8.91%
52-Week Range₹493.50 – ₹807.50
1-Year Price Change-14.8%
3-Month Price Change-18.3%
Beta (1Y)0.13
Dividend Yield0.63%
HeadquartersAhmedabad, Gujarat
Websitewww.concordbiotech.com

Latest Quarterly Results — Q2 FY27

Revenue₹309 Cr
Net Profit₹70 Cr
Net Margin22.5%
EPS (Basic)₹6.65
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Concord Biotech Ltd Quarterly Revenue and Profit Trend

Concord Biotech Ltd reported revenue of ₹309 Cr in Q2 FY27, up 25.1% from ₹247 Cr in Q2 FY26 and up 20.0% from ₹257 Cr in Q1 FY27. It posted a net profit of ₹70 Cr for the quarter, against a net profit of ₹63 Cr in Q2 FY26 (up 10.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹204 Cr (Q1 FY26) to ₹430 Cr (Q4 FY25). The company was profitable in each of these 7 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹309 Cr₹70 Cr22.5%
Q1 FY27₹257 Cr₹58 Cr22.4%
Q4 FY26₹326 Cr₹88 Cr27.1%
Q3 FY26₹278 Cr₹64 Cr22.9%
Q2 FY26₹247 Cr₹63 Cr25.5%
Q1 FY26₹204 Cr₹44 Cr21.6%
Q4 FY25₹430 Cr₹140 Cr32.7%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 44.09% of Concord Biotech Ltd's shares as of Sept 2026, against 44.08% in Sept 2025 (+0.01 percentage points). Delivery averaged 40.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Concord Biotech Ltd

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomyci

Products and Services

1. Manufacturing and trading in pharmaceutical products-This segment engages in researching, developing, manufacturing, marketing, and selling pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA

Business Segments

1. Manufacturing and trading in pharmaceutical products-100%

Concord Biotech Ltd vs Peers — Pharmaceutical CDMO and CRO Services

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Divis Laboratories Limited₹3,01,758 Cr118.416.19%₹3,676 Cr+71.9%
Anthem Biosciences Limited₹53,926 Cr90.119.45%₹594 Cr+34.5%
Sai Life Sciences Limited₹40,755 Cr116.115.13%₹659 Cr+120.3%
Onesource Specialty Pharma Limited₹18,138 Crn/m-1.26%₹516 Cr-9.4%
Cohance Lifesciences Ltd₹17,756 Cr100.65.11%₹477 Cr-35.2%
Syngene International Ltd.₹17,630 Cr56.96.62%₹833 Cr-27.9%
Jubilant Pharmova Ltd₹15,556 Cr39.15.96%₹2,370 Cr-14.5%
Concord Biotech Ltd₹12,495 Cr24.213.54%₹309 Cr-14.8%
Blue Jet Healthcare Ltd₹10,140 Cr3819.88%₹376 Cr-9.8%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Concord Biotech Ltd?

Concord Biotech Ltd is trading at ₹595.00, with a market capitalisation of ₹12,495 Cr.

Which sector does Concord Biotech Ltd belong to?

Concord Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).

What are the key financial ratios of Concord Biotech Ltd?

Concord Biotech Ltd has a P/E of 24.2 and a return on equity of 13.54%.

What is the stock symbol of Concord Biotech Ltd?

Concord Biotech Ltd is listed on the NSE under the symbol CONCORDBIO and on the BSE under the scrip code 543960.

How has Concord Biotech Ltd's share price moved over the past year?

Concord Biotech Ltd's share price is down 14.8% over one year and down 18.3% over three months. Its 52-week range is ₹493.50 to ₹807.50.

What were Concord Biotech Ltd's latest quarterly results?

In Q2 FY27, Concord Biotech Ltd reported revenue of ₹309 Cr and net profit of ₹70 Cr, with basic EPS of ₹6.65 (consolidated, parsed from the company's exchange filing).

How have Concord Biotech Ltd's revenue and profit changed over the past year?

Concord Biotech Ltd reported revenue of ₹309 Cr in Q2 FY27, up 25.1% from ₹247 Cr in Q2 FY26 and up 20.0% from ₹257 Cr in Q1 FY27.

What is the promoter holding in Concord Biotech Ltd?

Promoters held 44.09% of Concord Biotech Ltd's shares as of Sept 2026, against 44.08% in Sept 2025 (+0.01 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.